Home SiteMap SearchContactUs About Neotropix Products Technology Partnering News and Events Careers Peter Lanciano CEO Prior to joining Neotropix, Mr. Lanciano was a co-founder of Altus Pharmaceuticals [NASDAQ: ALTU], a company focused on GI and metabolic diseases. Mr. Lanciano led company growth an...

Clinical Trials Home SiteMap SearchContactUs About Neotropix Products Technology Partnering News and Events Careers Carcinoid Tumors Relatively new to medical recognition, carcinoid tumors were first identified as a tumor type in the mid 1800s and were not called carcinoid until the early 1900s. The...

Clinical Trials Home SiteMap SearchContactUs About Neotropix Products Technology Partnering News and Events Careers Pediatric Preclinical Testing Program (PPTP) evaluation of the oncolytic picornavirus, NTX-010 (SVV-001) NCI1-supported Pediatric Preclinical Testing Program to present testing results...

Clinical Trials Home SiteMap SearchContactUs About Neotropix Products Technology Partnering News and Events Careers Neotropix Announces Expansion of On-going Clinical Trial for Adult Neuroendocrine Cancers Receives Orphan Drug Designation for NTX-010 from the FDA Malvern, PA, October 8, 2008 Neotrop...

Clinical Trials Home SiteMap SearchContactUs About Neotropix Products Technology Partnering News and Events Careers Neotropix Site Map Home Page About Neotropix Advantages Clinical Advisory Board Management Partners Investor Information Partners Newsroom Board of Directors Management Carcinoid Conta...